Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor

Fig. 3

Prognostic analyses based on tumor subtyping. A–D Overall survival (OS) of all patients (A), MGMT promoter methylation patients (B), ATRX wild type patients (C) and TERT wild type patients (D) between astrocytoma and oligodendroglioma. E–H Progression-free interval (PFI) for all patients (E), MGMT promoter methylation patients (F), ATRX wild type patients (G), and TERT wild type patients (H) between astrocytoma and oligodendroglioma. I-J OS (I) and PFI (J) for astrocytoma patients regarding chr 7/chr 10 status. K–L OS (K) and PFI (L) for oligodendroglioma patients regarding chr 7/chr 4 status. OS overall survival, PFI progression-free interval, Astro astrocytoma, Oligo oligodendroglioma, pts patients. P-value was calculated by log-rank test

Back to article page

Molecular Medicine

ISSN: 1528-3658